
Model Evidences Wide Treatment Gap for Carbapenem-Resistant Gram-Negative Infections
Less than 7% of persons contracting carbapenem-resistant Gram negative (CRGN) infections across low- and middle-income countries (LMICs) receive appropriate antimicrobial treatment, according to new modeling1 estimates. The investigators attribute the …